OOIR: Observatory of International Research

Papers

(The H4-Index of Osteoporosis International is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
RE: “Race/ethnic differences in trabecular bone score in mid-life women: the Study of Women’s Health Across the Nation (SWAN)”	829
Dual-energy x-ray absorptiometry scanner mismatch in follow-up bone mineral density testing	348
Comment on “Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer”: Waxing-Waning Serum Calcium following Denosumab use in a patient with Polyostotic Paget’s Disease of Bone	108
The clinical trial landscape of anti-RANKL agents for osteoporosis: current status and future directions	103
Response to letter, re. “Comparison of fracture risk between type 1 and type 2 diabetes: a comprehensive real-world data”	97
A promising strategy for the diagnosis, treatment, and prevention of osteoporosis (EMS strategy)	85
Correction to: Author response to the comments on our article Relatively low and moderate pre-fracture serum 25-hydroxyvitamin D levels associated with the highest survival in elderly hip fracture pat	80
Incident peptic ulcers and concomitant treatment of direct oral anticoagulants and oral bisphosphonates—a real-world cohort study	66
Mineral-rich water consumption as a non-pharmacological intervention for early menopausal bone mineral density preservation and reduction of long-term fracture risk: comment on Billington et al. Osteo	62
The incidence of subsequent contralateral hip fracture and factors associated with increased risk: the IMPACT Contralateral Fracture Study	60
The association between blood cadmium levels and bone mineral density in U.S. adolescents aged 12–19 years	53
Follicle-stimulating hormone is associated with low bone mass in postmenopausal women	53
Bone mineral density assessment using radiofrequency echographic multispectrometry (REMS) in patients before and after total hip replacement	51
Impact of the guidance on fracture Liaison Services and the introduction of a new fee for secondary fracture prevention in Japan: Implementation of secondary fracture prevention during hospitalization	51
One versus 2 years of alendronate following denosumab: the CARD extension	49
RETRACTED ARTICLE: Evaluation of bone mineral density (BMD) and trabecular bone score (TBS) in pheochromocytoma and paraganglioma; a multi-centric case–control study from India	47
The link between osteoporosis and cardiovascular diseases: a review of shared mechanisms, risk factors, and therapeutic approaches	44
Comparison of the efficacy between sequential therapy with teriparatide and denosumab and denosumab monotherapy in suppressing fragility fracture risk	44
Trajectories of oral bisphosphonate use after hip fractures: a population-based cohort study	42
Changes in spinal sagittal balance after a new osteoporotic vertebral compression fracture	40
Epidemiology of pelvic and acetabular fractures in the USA from 2007 to 2014	40
The effects of β-carotene on osteoporosis: a systematic review and meta-analysis of observational studies	40
Return on investment of fracture liaison services: a systematic review and analysis	39
Scaffolds: a biomaterial engineering in targeted drug delivery for osteoporosis	38
Comparison of radiological and functional outcomes of conservative treatment with teriparatide and denosumab in thoracolumbar osteoporotic vertebral fracture	36

A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis	36
Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women	35
Latent metabolic bone disease, skeletal dysplasia and other conditions related to low bone formation among 38 patients with subtrochanteric femoral fractures: a retrospective observational study	35
Projected burden of femoral fracture surgeries in Japan through 2035: a nationwide population-based modeling study	35
Atypical femoral fracture after denosumab for the treatment of osteoporosis in bisphosphonate naïve patients: two further cases	34
Association between dental diseases and oral hygiene care and the risk of vertebral fracture: a nationwide cohort study	33
Bisphosphonate drug holidays in osteoporosis according to fracture risk profile	32